34 results about "Schistosomiasis japonicum" patented technology

The present invention discloses a medical test paper strip for a fast diagnosis of schistosomiasis japonicum in domestic animals. Said medical test paper strip in accordance with the present invention adopts SEA antibody and SEA coated nitrocellulose membrane as a quality control line and a detection line and is manufactured using a double antigen sandwich method, wherein the SEA antigen is labelled by colloidal gold. The present invention has a remarkable specificity and a high sensitivity, and is operated conveniently, simply and quickly. The present invention has a low manufacturing cost and then is suitable for a mass production.

The invention provides a kit for detecting the circulating antigen of oriental schistosomiasis, comprising streptavidin-coated magnetic beads, an oriental schistosomiasis resistant soluble egg antigen polyclonal antibody marked by biotin, an oriental schistosomiasis resistant soluble egg antigen specificity monoclonal antibody marked by an electrochemiluminescence reagent, a cleaning solution, a sample diluent, schistosomiasis positive serum, schistosomiasis negative serum and a co-reaction reagent. The invention further provides a method for detecting the circulating antigen of oriental schistosomiasis. In the invention, the kit for detecting the circulating antigen of oriental schistosomiasis is simple, convenient and fast in operation, is suitable for the clinic diagnosis, the curative effect check and the epidemiological investigation at the departments of hospital clinical laboratory, disease prevent and control center, community healthy center and the like, and has very high use value; and the double-antibody sandwich method for detecting the circulating antigen of oriental schistosomiasis has high sensitivity, strong specificity and good repeatability, and is suitable for the detection of batches of specimens and the curative effect check.

The invention discloses a urine biomarker for Japanese schistosomiasis early diagnosis. The urine biomarker is one or more of a xanthurenic acid, a naphthalenesulfonic acid, or enanthylcarnitine. Sensitivity and specificity of the marker are greater than 0.9, and an area under the curve (AUC) is greater than 0.9, indicating that the three indicators have better predictability and may be used for the Japanese schistosomiasis early diagnosis. The invention further discloses a metabolomics-based screening method for the urine biomarker for the Japanese schistosomiasis early diagnosis. By constructing a mouse Japanese schistosomiasis model, ultra performance liquid chromatography-tandem mass spectrometry is used to perform metabolomics analysis on mouse urine, and a characteristic differentialmetabolite, that is, the biomarker for the Japanese schistosomiasis early diagnosis, between a normal mouse and a Japanese schistosomiasis-infected mouse is found and analyzed. The screening method is non-invasive, convenient and fast, and can accurately reflect a metabolic spectrum difference between the Japanese schistosomiasis-infected mouse and the normal mouse and have high specificity.

The invention discloses a preparation method of a Schistosoma japonicum calcium-binding EF-hand domain containing protein (SjEFCAB) recombinant antigen protein. The preparation method comprises the following steps of: designing SEQ ID NO.3 or a complementary chain 5' thereof as a primer and SEQ ID NO.4 or a complementary chain 3' thereof as a primer, and carrying out amplification on a Schistosoma japonicum SjEFCAB gene sequence; establishing and identifying Schistosoma japonicum SjEFCAB recombinant plasmids; and carrying out induction expression, purification and the like on recombinant protein. Besides, the invention further discloses an application of the Schistosoma japonicum SjEFCAB recombinant antigen protein prepared by using the method in preparation of products for detecting a serum antibody of a Schistosoma japonicum patient. Enzyme linked immunosorbent assay (ELISA) proves that the Schistosoma japonicum SjEFCAB recombinant antigen protein has higher sensitivity and specificity when used for diagnosing the Schistosoma japonicum, is a potential candidate target of diagnosis, and can be used as a target antigen for diagnosing the Schistosoma japonicum.

The invention relates to schistosoma japonicum micro-ribonucleic acid (miRNA) and application thereof. Particularly, the invention discloses new miRNA which is separated out from schistosoma japonicum, wherein the miRNA can be specifically combined with a corresponding part of messenger RNA (mRNA) to influence the transcription effect of the corresponding mRNA so as to influence the expression of a corresponding gene. The invention also provides application of the identified schistosoma japonicum miRNA, a precursor sequence thereof, antisense oligonucleotide for adjusting the expression of the miRNA and the like in diagnosis, prevention and treatment of the schistosoma japonicum.

The invention discloses a serum biomarker for early diagnosis of schistosomiasis japonica. The serum biomarker is phosphatidylcholine and / or palmitoyl choline. The sensitivity and specificity of the marker are both greater than 0.9, and the under-curve area (AUC) is greater than 0.9, which indicates that the two indexes have favorable predictability and can be used for early diagnosis of schistosomiasis japonicum katsurada. The invention further discloses a screening method of the serum biomarker for early diagnosis of schistosomiasis japonica based on metabonomics. A mouse schistosomiasis japonica model is constructed, and the metabonomics analysis is carried out on mouse serum by utilizing an ultra-high performance liquid chromatography-tandem mass spectrometry technology, and characteristic differential metabolites between a normal mouse and a schistosomiasis japonica infected mouse are found and analyzed, namely, the schistosomiasis japonica early diagnosis biomarker is obtained. The screening method has the characteristics of convenience and quickness, can accurately reflect the metabolic spectrum difference between a schistosomiasis japonicum infected mouse and a normal mouse, and is high in specificity.

The invention relates to the field of genetic engineering antibody, and builds schistosoma japonicum immature egg soluble antigen (SIEA) single-chain antibody library for the first time. By screening the SIEA single-chain antibody library through an immuno-affinity screening technique, a specific single-chain antibody aiming at anti-schistosomiasis-japonica effective natural molecular vaccine SIEA26-28kDa is obtained. The obtainment of the specific single-chain antibody provides a foundation for treating schistosomiasis japonica, utilizing the specific single-chain antibody as a probe to screen schistosoma japonicum cDNA libraries and obtaining a corresponding gene sequence aiming at anti-schistosomiasis-japonica effective vaccine molecules more conveniently and rapidly.

The present invention provides genes highly expressed in Schistosoma japonicum schistosomulum and encoded proteins and application thereof. A whole-genome expression profile chip of Schistosoma japonicum is utilized to screen a series of genes highly expressed in Schistosoma japonicum schistosomulum, and antigen proteins encoded by genes which are SjScP27, SjScP80, SjScP84 and SjScP88 can be specifically recognized by serum of patients with schistosomiasis and show obvious positive reactions. ELISA detection proves that the antigen proteins have high sensitivity and specificity for Schistosomajaponicum detection, and can be used for developing diagnostic reagents for schistosomiasis japonica.

The present invention discloses Schistosoma japonicum specific male fluke protein and its gene sequence and specifically combined antibody as well as Schistosoma japonicum preventing and treating vaccine prepared with the specific male fluke protein as immunogen and the application of the specific male fluke protein in preparing medicine for preventing and treating Schistosoma japonicum. Applying the specific male fluke protein can inhibit the sexual maturity of female fluke and disturb the pairing of female and male flukes and the ovipositiom of female fluke, so as to treat schistosomiasis and prevent Schistosoma japonicum diffusion.

The invention relates to the technical field of biology and particularly discloses application of a schistosomulum japonicum high-expression gene or coding protein thereof. The invention provides application of schistosoma japonicum katsurada SjScP25 gene, SjScP37 gene or SjScP41 gene, or coding protein thereof or a biomaterial containing the genes in preparation of schistosoma japonicum katsuradavaccine or schistosoma japonicum katsurada medicines, and provides application of the schistosoma japonicum katsurada SjScP37 gene or coding protein thereof or a biomaterial containing the schistosoma japonicum katsurada SjScP37 gene in preparation of schistosoma japonicum katsurada detection reagents or kit or detection of schistosoma japonicum katsurada with nondiagnostic purpose. The schistosomulum japonicum high-expression gene serving as antigen to immunize mice to achieve a relatively good protection effect, can relieve, even resist schistosomiasis infection and can be applied to development of schistosomiasis vaccines. Furthermore, the schistosomulum japonicum high-expression gene or coding protein thereof have high sensitivity and specificity on schistosomiasis detection and can be used in development of schistosomulum japonicum diagnostic reagents.

The present invention discloses Schistosoma japonicum specific female fluke protein and its gene sequence and specifically combined antibody as well as Schistosoma japonicum preventing and treating vaccine prepared with the specific female fluke protein as immunogen and the application of the specific female fluke protein in preparing medicine for preventing and treating Schistosoma japonicum. Applying the specific female fluke protein can inhibit the ovipositiom of female fluke to treat schistosomiasis and prevent Schistosoma japonicum diffusion.

The invention discloses the application of human β-actin as a serological diagnostic marker for the occurrence of schistosomiasis hepatic fibrosis, and the amino acid sequence of the β-actin protein is shown in SEQ ID NO:1. The study found that in the liver of Schistosoma japonicum hepatic fibrosis mice and patient serum, the gene and protein levels of β-actin were unstable, and its content in the liver increased significantly with the development of fibrosis, and the content in serum increased with the development of fibrosis. The development of fibrosis was significantly reduced. Therefore, the expression level of β-actin has become an important diagnostic index for judging the occurrence of liver fibrosis and the degree of lesion in patients with schistosomiasis japonicum. By detecting the expression level of β-actin in peripheral blood of patients, it can provide more information for field investigation and clinical work. It is a simple, easy-to-operate, economical and scientific diagnostic technique for liver fibrosis in Schistosomiasis japonicum.

The present invention discloses a kind of Schistosoma japonicum specific female blood fluke protein its gene sequence and antibody combined specifically with the protein, as well as Schistosomiasis japonica preventing and treating vaccine prepared with the specific female blood fluke protein as the immunogen. In addition, the present invention also discloses the application of the Schistosoma japonicum specific female blood fluke protein in preparing medicine for preventing and treating Schistosomiasis japonica. The Schistosoma japonicum specific female blood fluke antigen protein of the present invention may be applied in inhibiting the oviposition of female blood fluke so as to treat Schistosomiasis japonica and prevent diffusion of Schistosoma japonicum.

The invention provides application of myricetin in preparation of a drug for treating schistosomiasis. By in-vitro observing an effect of the myricetin for resisting schistosoma japonicum and carryingout in-vivo experiment by establishing a schistosoma japonicum infected mouse model, it is found that the myricetin has good schistosoma japonicum killing effect and an improvement effect on liver fibrosis of schistosoma japonicum infected mice in vivo and in vitro. Moreover, the insecticidal effect of the myricetin is equivalent to that of positive drug praziquantel, the myricetin can replace the application of the positive drug praziquantel to schistosomiasis japonica, possibility is provided for avoiding clinical drug resistance, and the myricetin has a great application prospect.

The invention provides a schistosoma japonicum antigen protein rSjScP92 and an application thereof. A series of genes which are highly expressed in schistosoma japonicum schistosoma are screened by using a schistosoma japonicum schistosoma whole genome expression profile chip, and antigen proteins coded by the genes SjScP15, SjScP57 and SjScP92 can be specifically recognized by serum of a schistosomiasis patient and show a relatively strong positive reaction. ELISA (enzyme-linked immunosorbent assay) detection shows that the antigen proteins have high sensitivity and specificity when being used for detecting the schistosoma japonicum and can be used for developing a schistosoma japonicum disease diagnostic reagent. After mice immunized by the schistosoma japonicum antigen proteins SjScP15, SjScP57 and SjScP92 are attacked by insects, the immune protection effect shows that the SjScP15, the SjScP57 and the SjScP92 are expected to be developed into schistosomiasis vaccines.

The invention provides a gene highly expressed in schistosoma japonicum katsurada, and a coding protein and application thereof. A schistosoma japonicum whole genome expression profile chip is utilized to screen a series of genes highly expressed in schistosoma japonicum katsurada, wherein the antigen proteins coded by the genes SjScP27, SjScP80, SjScP84 and SjScP88 can be specifically recognizedby the serum of a schistosomiasis patient, and have strong positive reaction. The ELISA detection indicates that the antigen proteins have high sensitivity and specificity when being used for detecting schistosoma japonicum, and can be used for developing schistosoma japonicum diagnostic reagents.

The invention discloses a urine biological marker for early diagnosis of schistosomiasis japonica, wherein the urine biological marker is one or more of xanthonic acid, naphthalenesulfonic acid or heptanoylcarnitine. The sensitivity and specificity of the markers were all greater than 0.9, and the area under the curve (AUC) was greater than 0.9, indicating that the three indicators had good predictive performance and could be used for early diagnosis of schistosomiasis japonica. The invention also discloses a screening method for early diagnosis of schistosomiasis japonica urine biomarkers based on metabolomics. By constructing a mouse schistosomiasis japonica model, the ultra-high performance liquid chromatography-tandem mass spectrometry technology is used to metabolize mouse urine. The omics analysis found and analyzed the characteristic differential metabolites between normal mice and Schistosoma japonicum-infected mice, which were biomarkers for early diagnosis of Schistosomiasis japonicum. The screening method has the characteristics of non-invasiveness, convenience and quickness, and can accurately reflect the difference of the metabolic profile between the mice infected with schistosomiasis japonicum and the normal mice, and has high specificity.

The invention provides genes highly expressed in schistosomula japonicum as well as encoded proteins and application thereof. According to the invention, a series of genes highly expressed in schistosomula japonicum are screened by using a schistosomula japonicum whole genome expression profile chip; antigen proteins encoded by the genes SjScP27, SjScP80, SjScP84 and SjScP88 can be specifically recognized by serum of a schistosomiasis patient, and a strong positive reaction is shown. ELISA detection shows that the antigen proteins have high sensitivity and specificity when used for detecting schistosoma, and can be used for developing Japanese schistosomiasis diagnostic reagents.

The invention discloses an application of a schistosoma japonicum (SjPPase) recombinant antigen protein in therapy evaluation of the schistosoma japonicum and belongs to the field of immunology. An amino acid sequence of the schistosoma japonicum (SjPPase) recombinant antigen protein is as shown in SEQ ID NO:1, and the schistosoma japonicum (SjPPase) recombinant antigen protein is the protein capable of catalyzing hydrolysis of inorganic pyrophosphate (PPi) to generate phosphate. The application of the SjPPase recombinant protein in diagnosis of the schistosoma japonicum is provided for the first time, and the SjPPase recombinant protein can be applied to diagnosis of the schistosoma japonicum, is capable of carrying out therapy evaluation, and has a wide market space and relatively good social and economic benefits.

The invention provides a schistosoma japonicum katsurada mitochondrial molecular marker and an application thereof. Specifically, the invention discloses a method for identifying geographical isolates of schistosoma japonicum katsurada samples and / or for clustering regional populations of the schistosoma japonicum katsurada samples on the basis of a cluster analysis result of ND1, ND1, ND4 and 16S-12S rDNA gene sequences. The method disclosed by the invention is convenient and accurate and is high in stability; and the method is of great help to identify an original infection place of patients with schistosomiasis and to judge whether a case belongs to a primary type or an imported type. Meanwhile, the method also provides support for monitoring the schistosoma japonicum katsurada and for conducting researches on an epidemic status.

The invention discloses a serum biomarker for early diagnosis of schistosomiasis japonicum, and the serum biomarker is phosphatidylcholine and / or palmicholin. The sensitivity and specificity of the markers are both greater than 0.9, and the area under the curve (AUC) is greater than 0.9, indicating that these two indicators have better predictability and can be used for early diagnosis of schistosomiasis japonicum. The invention also discloses a metabolomics-based screening method for serum biomarkers for the early diagnosis of schistosomiasis japonicum, by constructing a mouse schistosomiasis model, and using ultra-high performance liquid chromatography-tandem mass spectrometry to perform metabolomics on mouse serum Analyze, discover and analyze the characteristic differential metabolites between normal mice and Schistosoma japonicum-infected mice, which are biomarkers for early diagnosis of Schistosomiasis japonicum. The screening method has the characteristics of convenience and quickness, can accurately reflect the difference in metabolic spectrum between mice infected with schistosomiasis japonicum and normal mice, and has high specificity.

The invention discloses application of a compound with a structural formula (I) in preparation of a drug used for resisting Schistosomiasis japonicum. According to the invention, through deep analysis of the synthetic route of aliphatic acid of Schistosomiasis japonicum, it is believed 3-oxoacyl-ACP reductase (OAR) participating in the synthetic route is a crucial rate-limiting enzyme; on such a basis, target screening of compounds and in vitro insecticidal activity tests are carried out, then inhibition of the selected compound with insecticidal activity on the activity of target protein OAR is analyzed, and finally, toxicity of the active compound on a host cell is assessed. The compound with the structural formula (I) has substantial insecticidal activity and the potential of becoming a lead compound for resistance of Schistosomiasis japonicum and provides a novel approach and means for treatment of Schistosomiasis japonicum.

The present invention discloses Schistosoma japonicum specific male fluke protein and its gene sequence and specifically combined antibody as well as Schistosoma japonicum preventing and treating vaccine prepared with the specific male fluke protein as immunogen and the application of the specific male fluke protein in preparing medicine for preventing and treating Schistosoma japonicum. Applying the specific male fluke protein can inhibit the sexual maturity of female fluke and disturb the pairing of female and male flukes and the ovipositiom of female fluke, so as to treat schistosomiasis and prevent Schistosoma japonicum diffusion.

The invention provides a gene highly expressed in Schistosoma japonicum larvae, its encoded protein and its application. The present invention screens a series of highly expressed genes in Schistosoma japonicum larvae by using the whole genome expression spectrum chip of Schistosoma japonicum, wherein the antigenic proteins encoded by the genes SjScP27, SjScP80, SjScP84, and SjScP88 can be specifically recognized by the serum of schistosomiasis patients, and present strong positive reaction. ELISA detection showed that these antigenic proteins had high sensitivity and specificity in detecting schistosomiasis, and could be used in the development of diagnostic reagents for schistosomiasis japonicum.

The invention provides a schistosoma japonicum antigen protein rSjScP15 and an application thereof. A series of genes which are highly expressed in schistosoma japonicum schistosoma are screened by using a schistosoma japonicum schistosoma whole genome expression profile chip, and antigen proteins coded by the genes SjScP15, SjScP57 and SjScP92 can be specifically recognized by serum of a schistosomiasis patient and show a relatively strong positive reaction. ELISA (enzyme-linked immunosorbent assay) detection shows that the antigen proteins have high sensitivity and specificity when being used for detecting the schistosoma japonicum and can be used for developing a schistosoma japonicum disease diagnostic reagent. After mice immunized by the schistosoma japonicum antigen proteins SjScP15, SjScP57 and SjScP92 are attacked by insects, the immune protection effect shows that the SjScP15, the SjScP57 and the SjScP92 are expected to be developed into schistosomiasis vaccines.

The invention provides application of piperlongumine compounds in preparation of drugs for treating schistosomiasis japonicas and a pharmaceutical composition, and belongs to the technical field of drug treatment. Different substituent groups are introduced to the alpha position of Michael double bonds of piperlongumine, the obtained piperlongumine compound has efficient treatment activity on schistosoma japonicum, and the IC50 value of 72-hour in-vitro anti-schistosoma japonicum activity of the piperlongumine compound is 1-5 times that of piperlongumine. Wherein the IC50 value of the 72-hour in-vitro anti-schistosoma japonicum katsurada activity of the compound 9 is equivalent to that of clinical medicine positive control praziquantel.